Indian Journal of Critical Care Case Report

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  4 (2025)
Volume  3 (2024)
Volume  2 (2023)
Volume  1 (2022)
Related articles

VOLUME 4 , ISSUE 1 ( January-February, 2025 ) > List of Articles

CASE REPORT

Ondansetron as a Cause of Transient Blindness: A Case Report

Ravi Jindal, Sumeet K Jhingan, Guneet Singh, Sanju Goel, Nitti K Kaushal

Keywords : Blindness, Case report, Ondansetron, Transient

Citation Information : Jindal R, Jhingan SK, Singh G, Goel S, Kaushal NK. Ondansetron as a Cause of Transient Blindness: A Case Report. 2025; 4 (1):28-29.

DOI: 10.5005/jp-journals-11006-0148

License: CC BY-NC 4.0

Published Online: 30-12-2024

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Aim and background: To study transient blindness caused by ondansetron, which is a very rare complication. Ondansetron is a selective 5-hydroxytryptamine receptor (5-HT-3) antagonist. It is a widely used antiemetic and has superior efficacy and safety compared with other antiemetics. However, transient blindness is a very rare complication of both oral and intravenous ondansetron. Case description: We present a case of a 76-year-old female with ondansetron-induced transient blindness. The cause of transient blindness was established after ruling out other causes with the help of neurological and ophthalmological examination and relevant investigations. Conclusion and clinical significance: Physicians should be aware of the potential for a rare complication of blindness due to ondansetron, which might confound with other causes of blindness in critical care and perioperatively.

PDF Share
  1. Cherian A, Maguire M. Transient blindness following intravenous ondansetron. Anaesthesia 2005;60:938–939. DOI: 10.1111/j.1365-2044.2005.04348.x
  2. Engin MMN, Kılıçaslan Ö, Kocabay K. Delirium and visual loss after intravenous ondansetron application in pediatric patient: a case report. J Pediatr Res Rev Rep 2020;2(3):1–2. DOI: 10.47363/JPRRR/2020(2)106
  3. Perez EA, Lembersky B, Kaywin P, et al. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1998;4:52–58. PMID: 9467047.
  4. Barus R, Potey C, Gautier S, et al. Ondansetron induced blindness: a pharmacovigilance database study. Expert Opin Drug Saf 2023;23(8):1017–1020. DOI: 10.1080/14740338.2023.2273334
  5. Babi MA, Gorman MJ, Cipolla MJ, et al. Ondansetron-related hemorrhagic posterior reversible encephalopathy syndrome (PRES) following gastric bypass. Springerplus 2016;5:18. DOI: 10.1186/s40064-015-1644-9
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.